We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Aquestive Therapeutics (AQST) Outpaced the Stock Market Today
Read MoreHide Full Article
Aquestive Therapeutics (AQST - Free Report) ended the recent trading session at $2.68, demonstrating a +1.52% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.06%. Meanwhile, the Dow gained 0.13%, and the Nasdaq, a tech-heavy index, added 0.24%.
Shares of the specialty pharmaceutical company have appreciated by 3.13% over the course of the past month, underperforming the Medical sector's gain of 3.52% and the S&P 500's gain of 6.45%.
Market participants will be closely following the financial results of Aquestive Therapeutics in its upcoming release. The company's upcoming EPS is projected at -$0.08, signifying a 65.22% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $11.79 million, indicating a 10.36% increase compared to the same quarter of the previous year.
Investors might also notice recent changes to analyst estimates for Aquestive Therapeutics. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. At present, Aquestive Therapeutics boasts a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 92, finds itself in the top 37% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Aquestive Therapeutics (AQST) Outpaced the Stock Market Today
Aquestive Therapeutics (AQST - Free Report) ended the recent trading session at $2.68, demonstrating a +1.52% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.06%. Meanwhile, the Dow gained 0.13%, and the Nasdaq, a tech-heavy index, added 0.24%.
Shares of the specialty pharmaceutical company have appreciated by 3.13% over the course of the past month, underperforming the Medical sector's gain of 3.52% and the S&P 500's gain of 6.45%.
Market participants will be closely following the financial results of Aquestive Therapeutics in its upcoming release. The company's upcoming EPS is projected at -$0.08, signifying a 65.22% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $11.79 million, indicating a 10.36% increase compared to the same quarter of the previous year.
Investors might also notice recent changes to analyst estimates for Aquestive Therapeutics. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. At present, Aquestive Therapeutics boasts a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 92, finds itself in the top 37% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.